Related Experiment Video
Updated: Jan 14, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
The Intranasal Administration of Semaphorin 3A Inhibitor in a Mouse Model of Olfactory Disorder
Aya Murai1, Minori Noda1, Aiko Shimizu1
1Otolaryngology - Head and Neck Surgery, Okayama University Hospital, Okayama, JPN.
Abstract:
This study investigated the effects of intranasal administration of a semaphorin 3A inhibitor (Sema3A-I) in a mouse model of olfactory disorder, where olfactory sensory neuron (OSN) axons had been severely damaged. We performed axotomy (transection of OSN axons) of the OSNs in mice and administered Sema3A‑I intranasally to seven mice and saline to another seven mice. Following treatment, we assessed the thickness of the olfactory epithelium and the regeneration ratio of OSN axons. Intranasal administration of Sema3A-I did not significantly promote OSN regeneration, axonal outgrowth, or improve axonal projection compared to saline administration. Although Sema3A-I administration showed some promotion of axonal outgrowth, the difference was not statistically significant. Continuous subcutaneous administration of Sema3A-I in rats after axotomy promotes OSN regeneration and axonal outgrowth. Given that intranasal administration is minimally invasive, we believe that it may still be a feasible route when combined with additional treatment strategies. Further investigation into administration methods and therapeutic combinations is warranted.

